Gibson, Dunn & Crutcher advised Jade Biosciences on the transaction, and Cooley advised the placement agents; while Goodwin Procter advised Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
Evercore Group L.L.C. acted as financial advisor to Merck in this transaction and Covington & Burling LLP acted as its legal advisor. Centerview Partners LLC acted...
You must be a Standard 1 Year member to access this content.
Goodwin advised Scholar Rock Holding Corporation on the offering. Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious...
You must be a Standard 1 Year member to access this content.
Arnold & Porter advised Coherus Biosciences Inc. on the deal, and Goodwin advised Surface Oncology. Coherus Biosciences Inc. (Coherus) announced its acquisition of Surface Oncology Inc. (Surface),...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the underwriters in the IPO while Goodwin advised PepGen. PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Senti Biosciences, while Davis Polk advised Dynamics Special Purpose Corp. on the deal. Senti Biosciences (“Senti Bio”) announced its definitive business combination agreement with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Absci, while Latham & Watkins represented the underwriters in the offering. Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins...
You must be a Standard 1 Year member to access this content.
